1-9 of 9
Adrian Harris
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A10: Upregulation of ADAM17 protease and HER ligands through a PKB negative feedback loop mediates acquired resistance to Trastuzumab in HER2 overexpressed breast cancer

Merel Gijsen, Peter King, Tim Perera, Peter Parker, Banafshe Larijani, Adrian Harris, Anthony Kong
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7_Supplement): A10.
https://doi.org/10.1158/1078-0432.TCME10-A10
Published: 02 February 2016
View article titled, Abstract A10: Upregulation of ADAM17 protease and HER ligands through a PKB negative feedback loop mediates acquired resistance to Trastuzumab in HER2 overexpressed breast cancer
Journal Articles

A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors

Elena Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother, Jennifer R. Diamond, Anne Younger, Wells A. Messersmith, Lieve Adriaens, Liming Liu, Richard J. Kao, Albert Thomas DiCioccio, Ana Kostic, Russell Leek, Adrian Harris, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2695–2703.
https://doi.org/10.1158/1078-0432.CCR-14-2797
Published: 14 June 2015
View article titled, A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
Open the PDF for A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells

Anthony Kong, Veronique Calleja, Pierre Leboucher, Adrian Harris, Peter Parker, Banafshe Larijani
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15_Supplement): A26.
Published: 15 August 2014
View article titled, HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells
Journal Articles

Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer

Paul Nathan, Martin Zweifel, Anwar R. Padhani, Dow-Mu Koh, Matthew Ng, David J. Collins, Adrian Harris, Craig Carden, Jon Smythe, Nita Fisher, N. Jane Taylor, J. James Stirling, Shiao-Ping Lu, Martin O. Leach, Gordon J.S. Rustin, Ian Judson
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3428–3439.
https://doi.org/10.1158/1078-0432.CCR-11-3376
Published: 14 June 2012
View article titled, Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
Open the PDF for Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer in another window
Journal Articles

A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors

Alison H.M. Reid, Andrew Protheroe, Gerhardt Attard, Nikki Hayward, Laura Vidal, James Spicer, Heather M. Shaw, Elizabeth A. Bone, Joanne Carter, Leon Hooftman, Adrian Harris, Johann S. De Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (15): 4978–4985.
https://doi.org/10.1158/1078-0432.CCR-09-0306
Published: 29 July 2009
View article titled, A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors
Open the PDF for A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

Ruth Plummer, Christopher Jones, Mark Middleton, Richard Wilson, Jeffrey Evans, Anna Olsen, Nicola Curtin, Alan Boddy, Peter McHugh, David Newell, Adrian Harris, Patrick Johnson, Heidi Steinfeldt, Raz Dewji, Diane Wang, Lesley Robson, Hilary Calvert
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7917–7923.
https://doi.org/10.1158/1078-0432.CCR-08-1223
Published: 01 December 2008
View article titled, Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors in another window
Journal Articles

A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer

Xiao-Jun Ma, Ranelle Salunga, Sonika Dahiya, Wilson Wang, Erin Carney, Virginie Durbecq, Adrian Harris, Paul Goss, Christos Sotiriou, Mark Erlander, Dennis Sgroi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2601–2608.
https://doi.org/10.1158/1078-0432.CCR-07-5026
Published: 01 May 2008
View article titled, A Five-Gene Molecular Grade Index and <em>HOXB13:IL17BR</em> Are Complementary Prognostic Factors in Early Stage Breast Cancer
Open the PDF for A Five-Gene Molecular Grade Index and <em>HOXB13:IL17BR</em> Are Complementary Prognostic Factors in Early Stage Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors

Patricia M. LoRusso, Roy S. Herbst, Danny Rischin, Malcolm Ranson, Hilary Calvert, Eric Raymond, Dirk Kieback, Stan Kaye, Luca Gianni, Adrian Harris, Thomas Bjork, Anne-Marie Maddox, Mace L. Rothenberg, Eric J. Small, Eric H. Rubin, Andrea Feyereislova, Anne Heyes, Steven D. Averbuch, Judith Ochs, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (6): 2040–2048.
Published: 01 June 2003
View article titled, Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors
Open the PDF for Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors in another window
Journal Articles

Total Levels of Tissue Inhibitor of Metalloproteinases 1 in Plasma Yield High Diagnostic Sensitivity and Specificity in Patients with Colon Cancer

Mads N. Holten-Andersen, Ib Jarle Christensen, Hans Jørgen Nielsen, Ross W. Stephens, Vibeke Jensen, Ole Haagen Nielsen, Steen Sørensen, Jens Overgaard, Hans Lilja, Adrian Harris, Gillian Murphy, Nils Brünner
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (1): 156–164.
Published: 01 January 2002
View article titled, Total Levels of Tissue Inhibitor of Metalloproteinases 1 in Plasma Yield High Diagnostic Sensitivity and Specificity in Patients with Colon Cancer
Open the PDF for Total Levels of Tissue Inhibitor of Metalloproteinases 1 in Plasma Yield High Diagnostic Sensitivity and Specificity in Patients with Colon Cancer in another window